Translational Development Acquisition Corp. (TDAC) Research
Translational Development Acquisition Corp., founded in 2022 and headquartered in New York, New York, currently conducts no significant business operations. Its primary goal is to complete a business combination, such as a merger, amalgamation, share exchange, asset acquisition, share purchase, or reorganization, with one or more companies.
Market snapshot
- Symbol
- TDAC
- Price
- $10.75
- Day change
- +0.09%
- Market cap
- $235.5M
- P/E ratio
- 29.85x
- 52-week range
- 10.27-10.8
- Sector
- Financial Services
- Industry
- Shell Companies
Peer companies
- Cantor Equity Partners, Inc. Class A Ordinary Shares (CEP)
- Cantor Equity Partners I, Inc. Class A Ordinary Shares (CEPO)
- FACT II Acquisition Corp (FACT)
- HCM Acquisition Corp (HCMA)
- Melar Acquisition Corp. I (MACI)
- Newbury Street II Acquisition Corp (NTWO)
- Sizzle Acquisition Corp. II (SZZL)
- Willow Lane Acquisition Corp. (WLACU)
Recent insider activity
- Hoffman Michael B — P-Purchase (53395 shares) on 2026-05-27
- Jarratt Christopher Kenneth — trade (0 shares) on 2024-12-20
- Keith Curtis T — trade (0 shares) on 2024-12-20
- TDAC Partners LLC — trade (4657500 shares) on 2024-12-20
- Reddy E Premkumar — trade (0 shares) on 2024-12-20
Open Translational Development Acquisition Corp. (TDAC) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.